MedTrace Logo

Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

NCT04163575 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-12-23

No results posted yet for this study

Summary

This study aims to evaluate the safety, efficacy and duration of response of CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD22+ haematological malignancies.

Conditions

Interventions

BIOLOGICAL

:Anti-CD22-CAR

Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)

Sponsors & Collaborators

  • Hebei Yanda Ludaopei Hospital

    collaborator OTHER

  • Kecellitics Biotech Company Ltd

    lead INDUSTRY

Principal Investigators

  • Li xiangqun · Kecellitics Biotech Company Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-07-01
Completion
2022-07-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04163575 on ClinicalTrials.gov